While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.
Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use a variety of methods, including tried-and-true valuation metrics, to find these stocks.
On top of the Zacks Rank, investors can also look at our innovative Style Scores system to find stocks with specific traits. For example, value investors will want to focus on the "Value" category. Stocks with high Zacks Ranks and "A" grades for Value will be some of the highest-quality value stocks on the market today.
One stock to keep an eye on is Molina Healthcare (MOH - Free Report) . MOH is currently sporting a Zacks Rank #1 (Strong Buy), as well as an A grade for Value. The stock holds a P/E ratio of 9.08, while its industry has an average P/E of 17.77. Over the past year, MOH's Forward P/E has been as high as 13.98 and as low as 6.48, with a median of 11.46.
Another notable valuation metric for MOH is its P/B ratio of 2.06. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. This stock's P/B looks solid versus its industry's average P/B of 2.94. Over the past 12 months, MOH's P/B has been as high as 4.44 and as low as 1.79, with a median of 3.71.
Value investors also frequently use the P/S ratio. This metric is found by dividing a stock's price with the company's revenue. Some people prefer this metric because sales are harder to manipulate on an income statement. This means it could be a truer performance indicator. MOH has a P/S ratio of 0.23. This compares to its industry's average P/S of 0.31.
These figures are just a handful of the metrics value investors tend to look at, but they help show that Molina Healthcare is likely being undervalued right now. Considering this, as well as the strength of its earnings outlook, MOH feels like a great value stock at the moment.
On July 23, 2026, Molina Healthcare Inc (MOH) shares fell 9.7%, closing at $200.29. This decline comes amid a broader context of price fluctuations, with the st
Key Takeaways Molina Healthcare beat Q2 earnings estimates despite lower revenues, premium income and membership.MOH benefited from lower operating expenses but faced higher medical cost ratio and weaker investment income.MOH Healthcare raised 2026 EPS and adjusted net income guidance while reaffirming premium revenue outlook. Molina Healthcare, Inc. (MOH - Free Report) reported second-quarter 2026 adjusted earnings per share (EPS) of $1.51, which beat the Zacks Consensus Estimate by 10.2%. The bottom line declined 72.4% from the year-ago period's level.
Revenues amounted to $10.9 billion, which decreased 4.8% year over year. The top line marginally missed the consensus mark by 0.08%.
Second-quarter earnings benefited from lower operating expenses. However, lower premium revenues, declining membership, and weaker investment income weighed on its performance.
Molina Healthcare, Inc Price, Consensus and EPS SurpriseMOH’s Q2 Operational UpdatePremium revenues of $10.2 billion decreased 5.7% year over year and missed the Zacks Consensus Estimate by 1.8%. The decline primarily reflected lower membership levels, partially offset by pricing actions.
As of June 30, 2026, total membership decreased 14.3% year over year to around 4.9 million and missed the Zacks Consensus Estimate by 1.6%. The health insurer witnessed a year-over-year decrease in customers across all segments, especially in Marketplace and Other.
Investment income declined 4.7% year over year to $101 million. The figure beat the Zacks Consensus Estimate by 1.8%.
Total operating expenses were $10.7 billion, down 2.9% year over year and slightly below our model estimate of $11 billion, driven by lower medical care costs. The adjusted general and administrative expense ratio increased to 6.5% from 6.1% a year ago. Interest expense increased 12.5% year over year to $54 million.
The consolidated MCR (medical costs as a percentage of premium revenues) was 92.2% in the reported quarter. It rose from 90.4% a year ago but was marginally below the Zacks Consensus Estimate of 92.5%.
Molina Healthcare’s adjusted net income decreased 73.8% year over year to $77 million.
MOH’s Q2 Financial UpdateMolina Healthcare exited the second quarter with cash and cash equivalents of $5 billion, which increased from the 2025-end level of $4.2 billion. Total assets of $16 billion rose from $15.6 billion as of 2025-end.
Long-term debt totaled $3.8 billion, which remained unchanged from the 2025-end level.
Total stockholders’ equity of $4.2 billion inched up from $4.1 billion at the end of 2025.
Net cash provided by operating activities was $788 million compared to net cash used in operating activities of $112 million in the prior-year period.
MOH’s 2026 GuidanceThe company's full-year 2026 premium revenue guidance has remained unchanged at about $42 billion, down roughly 2% from 2025.
Management expects 2026 GAAP earnings of at least $2.15 per diluted share, up from its previous guidance of at least $1.90. It also raised its full-year 2026 adjusted earnings guidance by $0.25 to at least $5.25 per diluted share.
MOH raised its 2026 adjusted net income guidance to $268 million from $256 million. It also increased its GAAP net income guidance to $110 million from the previous estimate of $97 million.
MOH’s Zacks Rank & Key PicksMolina currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader Medical space are Humana Inc. (HUM - Free Report) , currently sporting a Zacks Rank #1 (Strong Buy), and CVS Health Corporation (CVS - Free Report) and Cencora, Inc. (COR - Free Report) , both carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Humana is set to report second-quarter 2026 results on July 29, before the market closes. The Zacks Consensus Estimate for earnings is pegged at $6.22 per share, which has witnessed three upward revisions over the past 60 days, with no movement in the opposite direction. The company beat on earnings in three of the trailing four quarters and missed once, with the average surprise being 3.8%. The consensus estimate for Humana’s second-quarter revenues is pinned at $40.65 billion, indicating a 25.5% year-over-year increase.
CVS Health is set to report second-quarter 2026 results on Aug. 5, before the market closes. The Zacks Consensus Estimate for earnings is pegged at $1.87 per share, indicating a 3.3% year-over-year increase. The company beat on earnings in each of the trailing four quarters, with the average surprise being 16.8%. The consensus estimate for CVS Health’s second-quarter revenues is pinned at $100.18 billion, indicating a 1.3% year-over-year increase.
Cencora is set to report second-quarter 2026 results on Aug. 5, before the market closes. The Zacks Consensus Estimate for earnings is pegged at $4.37 per share, indicating a 9.3% year-over-year increase. The company beat on earnings in three of the trailing four quarters and missed once, with the average surprise being 1.6%. The consensus estimate for Cencora’s second-quarter revenues is pinned at $84.89 billion, indicating a 5.2% year-over-year increase.
Molina (MOH - Free Report) reported $10.87 billion in revenue for the quarter ended June 2026, representing a year-over-year decline of 4.8%. EPS of $1.51 for the same period compares to $5.48 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $10.88 billion, representing a surprise of -0.08%. The company delivered an EPS surprise of +10.22%, with the consensus EPS estimate being $1.37.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Molina performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
MCR - Medicaid: 92.7% compared to the 92.9% average estimate based on three analysts.MCR - Medicare: 90.7% versus 93.7% estimated by three analysts on average.MCR - Marketplace: 88.9% versus the three-analyst average estimate of 84.9%.Ending Membership by Program - Total: 4.93 million versus 5 million estimated by three analysts on average.Ending Membership by Program - Medicaid: 4.42 million versus the three-analyst average estimate of 4.48 million.Revenue- Premium revenue- Marketplace: $628 million versus the three-analyst average estimate of $643.41 million. The reported number represents a year-over-year change of -47.7%.Revenue- Premium tax revenue: $505 million versus the three-analyst average estimate of $437.04 million. The reported number represents a year-over-year change of +17.2%.Revenue- Premium revenue- Medicaid: $8.05 billion compared to the $8.16 billion average estimate based on three analysts. The reported number represents a change of +0.3% year over year.Revenue- Premium revenue- Medicare: $1.57 billion versus the three-analyst average estimate of $1.63 billion. The reported number represents a year-over-year change of -2.7%.Revenue- Premium revenue: $10.24 billion compared to the $10.43 billion average estimate based on three analysts. The reported number represents a change of -5.7% year over year.Revenue- Other revenue: $24 million versus $22.26 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +9.1% change.Revenue- Investment income: $101 million versus $99.18 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -4.7% change.View all Key Company Metrics for Molina here>>>
Shares of Molina have returned +15.3% over the past month versus the Zacks S&P 500 composite's +0.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Molina (MOH - Free Report) came out with quarterly earnings of $1.51 per share, beating the Zacks Consensus Estimate of $1.37 per share. This compares to earnings of $5.48 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of +10.22%. A quarter ago, it was expected that this provider of Medicaid-related services would post earnings of $1.57 per share when it actually produced earnings of $2.35, delivering a surprise of +49.68%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.
Molina, which belongs to the Zacks Medical - HMOs industry, posted revenues of $10.87 billion for the quarter ended June 2026, missing the Zacks Consensus Estimate by 0.08%. This compares to year-ago revenues of $11.43 billion. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Molina shares have added about 30.5% since the beginning of the year versus the S&P 500's gain of 9.7%.
What's Next for Molina?While Molina has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.
Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.
Ahead of this earnings release, the estimate revisions trend for Molina was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.01 on $11.06 billion in revenues for the coming quarter and $5.23 on $44.41 billion in revenues for the current fiscal year.
Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - HMOs is currently in the top 10% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.
The Joint Corp. (JYNT - Free Report) , another stock in the same industry, has yet to report results for the quarter ended June 2026.
This company is expected to post quarterly earnings of $0.11 per share in its upcoming report, which represents a year-over-year change of +283.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.
The Joint Corp.'s revenues are expected to be $14.7 million, up 10.7% from the year-ago quarter.
LONG BEACH, Calif.--(BUSINESS WIRE)--Molina Healthcare, Inc. (NYSE: MOH) (the “Company”) today reported second quarter 2026 GAAP income per diluted share of $1.19 and adjusted income per diluted share of $1.51. Financial results are summarized below:
Three months ended
Six months ended
June 30,
June 30,
2026
2025
2026
2025
(In millions, except per-share results)
Premium Revenue
$10,244
$10,868
$20,416
$21,496
Total Revenue
$10,874
$11,427
$21,670
$22,574
GAAP:
Net Income
$60
$255
$74
$553
EPS – Diluted
$1.19
$4.75
$1.46
$10.19
Medical Care Ratio (MCR)
92.2%
90.4%
91.6%
89.8%
G&A Ratio
6.7%
6.2%
6.9%
6.6%
Pre-tax Margin
0.8%
2.8%
0.6%
3.2%
Adjusted:
Net Income
$77
$294
$197
$627
EPS – Diluted
$1.51
$5.48
$3.86
$11.56
G&A Ratio
6.5%
6.1%
6.7%
6.4%
Pre-tax Margin
1.0%
3.3%
1.3%
3.6%
See the Reconciliation of Unaudited Non-GAAP Financial Measures at the end of this release.
Quarter Highlights
As of June 30, 2026, the Company served approximately 4.9 million members. Premium revenue was approximately $10.2 billion for the second quarter of 2026. Second quarter 2026 GAAP income per diluted share was $1.19 and adjusted income per diluted share was $1.51. The Company increased its full year 2026 adjusted earnings guidance by $0.25 to at least $5.25 per diluted share. “Our second quarter results and full year guidance reflect solid performance in our Medicaid and Medicare segments,” said Joseph Zubretsky, President and Chief Executive Officer. “The imbalance between Medicaid rates and medical cost trend appears to have stabilized and is well positioned to be corrected with future rate increases. This reinforces our belief that 2026 is the trough year for Medicaid pretax margins. We remain confident in our disciplined approach to medical cost management and believe the premium and EPS building blocks position us well for profitable growth in 2027.”
Premium Revenue
Premium revenue was approximately $10.2 billion for the second quarter of 2026, a decrease of 6% year over year. The lower premium revenue reflects the impact of lower membership, partially offset by rate updates.
Net Income
GAAP net income for the second quarter of 2026 was $60 million, or $1.19 per diluted share, a decrease of 76% year over year. Adjusted net income for the second quarter of 2026 was $77 million, or $1.51 per diluted share, a decrease of 74% year over year. The decrease is attributed mainly to the lower premium revenues and increase in MCR.
Medical Care Ratio (MCR)
The consolidated MCR for the second quarter of 2026 was 92.2%. The Medicaid MCR for the second quarter of 2026 was 92.7% and in line with the Company’s expectation, reflecting rate updates and stable medical cost trend. The Medicare MCR for the second quarter of 2026 was 90.7% and better than the Company’s expectation, reflecting lower medical cost trend and pricing implemented for 2026. The Marketplace MCR for the second quarter of 2026 was 88.9% and higher than the Company’s expectations, reflecting prior year risk adjustment and program integrity initiatives and the impact of current year unfavorable member acuity mix. General and Administrative Expense Ratio
The G&A ratio and the adjusted G&A ratio for the second quarter of 2026 were 6.7% and 6.5%, respectively, reflecting continued operating discipline.
Balance Sheet
Cash and investments at the parent company were approximately $290 million as of June 30, 2026, compared to $223 million as of December 31, 2025.
Days in claims payable at June 30, 2026, was 44.
Cash Flow
Operating cash flow for the six months ended June 30, 2026, was $788 million, compared to an outflow of $112 million for the six months ended June 30, 2025. The increase compared to the prior year was driven mainly by the timing of government receivables and payables.
2026 Guidance
Premium revenue guidance for the full year is unchanged at approximately $42 billion.
The Company increased its full year 2026 GAAP earnings to at least $2.15 per diluted share and its full year 2026 adjusted earnings to at least $5.25 per diluted share. The increase to earnings guidance reflects first half performance in Medicaid. Based on developing medical cost trends, a $1.50 increase in earnings per share in Medicare is offset by a $1.50 decrease related to Marketplace. Excluding the downward revision in the Marketplace guidance, the full year guidance would have increased to $6.75 per share.
Full year guidance includes a loss of $1.50 per share due to the implementation of the new Florida Medicaid contract in the fourth quarter of 2026 and a loss of $1.00 per share due to performance of the traditional MAPD product, which the Company previously announced it will exit for 2027.
Conference Call
Management will host a conference call and webcast to discuss Molina Healthcare’s second quarter ended June 30, 2026 results, at 8:00 a.m. Eastern Time on Thursday, July 23, 2026. The number to call for the interactive teleconference is (877) 883-0383 and the confirmation number is 8631129. A telephonic replay of the conference call will be available through Thursday, July 30, 2026, by dialing (855) 669-9658 and entering confirmation number 6469068. A live audio broadcast of this conference call will be available on Molina Healthcare’s investor relations website, investors.molinahealthcare.com. A 30-day online replay will be available approximately an hour following the conclusion of the live broadcast.
About Molina Healthcare
Molina Healthcare, Inc., a FORTUNE 500 company, provides managed healthcare services under the Medicaid and Medicare programs and through the state insurance marketplaces. For more information about Molina Healthcare, please visit molinahealthcare.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
This earnings release and the Company’s accompanying oral remarks contain forward-looking statements. The Company intends such forward-looking statements to be covered under the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements provide current expectations of future events based on certain assumptions, and all statements other than statements of historical fact contained in this earnings release and the Company’s accompanying oral remarks may be forward-looking statements. In some cases, you can identify forward-looking statements by words such as “guidance,” “future,” “anticipates,” “assumes,” “believes,” “embedded,” “estimates,” “expects,” “growth,” “intends,” “plans,” “predicts,” “projects,” “will,” “would,” “could,” “can,” “may,” or the negative of these terms or other similar expressions. Forward-looking statements contained in this earnings release include, but are not limited to, statements regarding the Company’s 2026 guidance and long-term performance outlook, trends with respect to rates, pretax margins, utilization, and medical costs, including the timing thereof and the anticipated impact on the Company’s business, and our management’s plans and objectives for future operations and business strategy.
Actual results could differ materially due to numerous known and unknown risks and uncertainties. These risks and uncertainties are discussed under the headings “Forward-Looking Statements,” and “Risk Factors,” in the Company’s Annual Report on Form 10‑K for the year ended December 31, 2025, which is on file with the U.S. Securities and Exchange Commission (the “SEC”), and in the Company’s other filings with the SEC, including its Quarterly Report on Form 10-Q for the period ended March 31, 2026 filed with the SEC and Quarterly Report on Form 10-Q for the period ended June 30, 2026, to be filed with the SEC.
These reports can be accessed under the investor relations tab of the Company’s website or on the SEC’s website at sec.gov. Given these risks and uncertainties, the Company can give no assurances that its forward-looking statements will prove to be accurate, or that any other results or developments projected or contemplated by its forward-looking statements will in fact occur, and the Company cautions investors not to place undue reliance on these statements. All forward-looking statements in this release represent the Company’s judgment as of July 22, 2026, and, except as otherwise required by law, the Company disclaims any obligation to update any forward-looking statement to conform the statement to actual results or changes in its expectations.
MOLINA HEALTHCARE, INC.
UNAUDITED CONSOLIDATED STATEMENTS OF INCOME
Three Months Ended
Six Months Ended
June 30,
June 30,
2026
2025
2026
2025
(In millions, except per-share amounts)
Revenue:
Premium revenue
$
10,244
$
10,868
$
20,416
$
21,496
Premium tax revenue
505
431
1,009
819
Investment income
101
106
199
214
Other revenue
24
22
46
45
Total revenue
10,874
11,427
21,670
22,574
Operating expenses:
Medical care costs
9,440
9,829
18,710
19,308
General and administrative expenses
724
711
1,503
1,485
Premium tax expenses
505
431
1,009
819
Depreciation and amortization
40
58
79
106
Impairment
—
—
93
—
Other
20
25
48
50
Total operating expenses
10,729
11,054
21,442
21,768
Operating income
145
373
228
806
Interest expense
54
48
108
91
Income before income tax expense
91
325
120
715
Income tax expense
31
70
46
162
Net income
$
60
$
255
$
74
$
553
Net income per share – Diluted
$
1.19
$
4.75
$
1.46
$
10.19
Diluted weighted average shares outstanding
51.3
53.7
51.2
54.3
MOLINA HEALTHCARE, INC.
CONSOLIDATED BALANCE SHEETS
June 30,
December 31,
2026
2025
Unaudited
(Dollars in millions,
except per-share amounts)
ASSETS
Current assets:
Cash and cash equivalents
$
4,985
$
4,248
Investments
3,930
4,008
Receivables
3,485
3,533
Prepaid expenses and other current assets
528
655
Total current assets
12,928
12,444
Property, equipment, and capitalized software, net
311
301
Goodwill and intangible assets, net
2,082
2,195
Restricted investments
313
299
Deferred income taxes, net
229
178
Other assets
140
147
Total assets
$
16,003
$
15,564
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Medical claims and benefits payable
$
4,841
$
4,887
Amounts due government agencies
1,651
1,326
Accounts payable, accrued liabilities and other
1,139
1,093
Deferred revenue
69
66
Total current liabilities
7,700
7,372
Long-term debt
3,769
3,766
Finance lease liabilities
184
184
Other long-term liabilities
179
173
Total liabilities
11,832
11,495
Stockholders’ equity:
Common stock, $0.001 par value, 150 million shares authorized; outstanding: 52 million shares at June 30, 2026, and 51 million at December 31, 2025
—
—
Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding
—
—
Additional paid-in capital
511
452
Accumulated other comprehensive (loss) income
(16
)
15
Retained earnings
3,676
3,602
Total stockholders’ equity
4,171
4,069
Total liabilities and stockholders’ equity
$
16,003
$
15,564
MOLINA HEALTHCARE, INC.
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS
Six Months Ended
June 30,
2026
2025
(In millions)
Operating activities:
Net income
$
74
$
553
Adjustments to reconcile net income to net cash provided by (used in) operating activities:
Depreciation and amortization
79
106
Deferred income taxes
(41
)
22
Share-based compensation
59
30
Impairment
93
—
Other, net
(2
)
—
Changes in operating assets and liabilities:
Receivables
48
(466
)
Prepaid expenses and other current assets
9
10
Medical claims and benefits payable
(46
)
(50
)
Amounts due government agencies
325
(81
)
Accounts payable, accrued liabilities and other
66
(301
)
Deferred revenue
3
(59
)
Income taxes
121
124
Net cash provided by (used in) operating activities
788
(112
)
Investing activities:
Purchases of investments
(626
)
(421
)
Proceeds from sales and maturities of investments
672
717
Purchases of property, equipment, and capitalized software
(57
)
(64
)
Net cash paid in business combinations
—
(245
)
Other, net
(8
)
18
Net cash (used in) provided by investing activities
(19
)
5
Financing activities:
Proceeds from borrowings under credit facility and term loans
—
650
Common stock purchases
—
(500
)
Repayment of credit facility and term loans
—
(200
)
Common stock withheld to settle employee tax obligations
(14
)
(36
)
Other, net
(10
)
44
Net cash used in financing activities
(24
)
(42
)
Net increase (decrease) in cash, cash equivalents, and restricted cash and cash equivalents
745
(149
)
Cash, cash equivalents, and restricted cash and cash equivalents at beginning of period
4,348
4,741
Cash, cash equivalents, and restricted cash and cash equivalents at end of period
$
5,093
$
4,592
MOLINA HEALTHCARE, INC.
UNAUDITED SEGMENT DATA
(Dollars in millions)
June 30,
December 31,
June 30,
2026
2025
2025
Ending Membership by Segment:
Medicaid
4,418,000
4,568,000
4,774,000
Medicare
224,000
262,000
267,000
Marketplace
283,000
655,000
690,000
Other
1,000
6,000
15,000
Total
4,926,000
5,491,000
5,746,000
Three Months Ended June 30,
2026
2025
Premium Revenue
Medical
Margin
MCR (1)
Premium Revenue
Medical
Margin
MCR (1)
Medicaid
$
8,049
$
585
92.7
%
$
8,029
$
697
91.3
%
Medicare
1,565
146
90.7
1,608
161
90.0
Marketplace
628
69
88.9
1,200
175
85.4
Other (2)
2
4
NM
31
6
NM
Consolidated
$
10,244
$
804
92.2
%
$
10,868
$
1,039
90.4
%
Six Months Ended June 30,
2026
2025
Premium Revenue
Medical
Margin
MCR (1)
Premium Revenue
Medical
Margin
MCR (1)
Medicaid
$
15,976
$
1,216
92.4
%
$
16,159
$
1,488
90.8
%
Medicare
3,082
300
90.3
3,076
333
89.2
Marketplace
1,352
185
86.3
2,204
358
83.7
Other (2)
6
5
NM
57
9
NM
Consolidated
$
20,416
$
1,706
91.6
%
$
21,496
$
2,188
89.8
%
(1) The MCR represents medical costs as a percentage of premium revenue.
(2) The Other MCRs are not meaningful.
MOLINA HEALTHCARE, INC.
CHANGE IN MEDICAL CLAIMS AND BENEFITS PAYABLE
(Dollars in millions)
The Company’s claims liabilities include additional reserves to account for moderately adverse conditions based on historical experience and other factors including, but not limited to, variations in claims payment patterns, changes in utilization and cost trends, known outbreaks of disease, and large claims. The Company’s reserving methodology is consistently applied across all periods presented. The amounts displayed for “Components of medical care costs related to: Prior year” represent the amounts by which the original estimates of claims and benefits payable at the beginning of the year were more than the actual liabilities based on information (principally the payment of claims) developed since those liabilities were first reported. The following table presents the components of the change in medical claims and benefits payable for the periods indicated:
Six Months Ended
June 30,
2026
2025
Unaudited
Medical claims and benefits payable, beginning balance
$
4,887
$
4,640
Components of medical care costs related to:
Current year
18,995
19,509
Prior year
(285
)
(201
)
Total medical care costs
18,710
19,308
Payments for medical care costs related to:
Current year
15,062
15,700
Prior year
3,918
3,918
Total paid
18,980
19,618
Acquired balances, net of post-acquisition adjustments
—
295
Change in non-risk and other payables
224
260
Medical claims and benefits payable, ending balance
$
4,841
$
4,885
Days in Claims Payable (1)
44
43
__________________
MOLINA HEALTHCARE, INC.
RECONCILIATION OF UNAUDITED NON-GAAP FINANCIAL MEASURES
(In millions, except per diluted share amounts)
The Company believes that certain non-GAAP (generally accepted accounting principles) financial measures are useful supplemental measures to investors in comparing the Company’s performance to the performance of other public companies in the health care industry. The non-GAAP financial measures are also used internally to enable management to assess the Company’s performance consistently over time. These non-GAAP financial measures, presented below, should be considered as supplements to, and not as substitutes for or superior to, GAAP measures.
Adjustments represent additions and deductions to GAAP net income as indicated in the table below, which include the non-cash impact of amortization of acquired intangible assets, acquisition-related expenses, impairments, and the impact of certain expenses and other items that management believes are not indicative of longer-term business trends and operations.
Adjusted G&A Ratio represents the GAAP G&A ratio, recognizing adjustments.
Adjusted net income represents GAAP net income recognizing the adjustments, net of tax. The Company believes that adjusted net income is helpful to investors in assessing the Company’s financial performance.
Adjusted net income per diluted share represents adjusted net income divided by weighted average common shares outstanding on a fully diluted basis.
Adjusted pre-tax margin represents adjusted income before income tax expense, divided by total revenue.
Three Months Ended June 30,
Six Months Ended June 30,
2026
2025
2026
2025
Amount
Per Diluted Share
Amount
Per Diluted Share
Amount
Per Diluted Share
Amount
Per Diluted Share
GAAP Net income
$
60
$
1.19
$
255
$
4.75
$
74
$
1.46
$
553
$
10.19
Adjustments:
Amortization of intangible assets
$
9
$
0.18
$
32
$
0.60
$
19
$
0.38
$
53
$
0.99
Acquisition-related expenses (1)
12
0.23
19
0.37
33
0.64
42
0.78
Impairment (2)
—
—
—
—
93
1.82
—
—
Other (3)
—
—
—
—
21
0.41
2
0.03
Subtotal, adjustments
21
0.41
51
0.97
166
3.25
97
1.80
Income tax effect
(4
)
(0.09
)
(12
)
(0.24
)
(43
)
(0.85
)
(23
)
(0.43
)
Adjustments, net of tax
17
0.32
39
0.73
123
2.40
74
1.37
Adjusted net income
$
77
$
1.51
$
294
$
5.48
$
197
$
3.86
$
627
$
11.56
__________________
MOLINA HEALTHCARE, INC.
RECONCILIATION OF UNAUDITED NON-GAAP FINANCIAL MEASURES (CONTINUED)
Analysts on Wall Street project that Molina (MOH - Free Report) will announce quarterly earnings of $1.37 per share in its forthcoming report, representing a decline of 75% year over year. Revenues are projected to reach $10.88 billion, declining 4.8% from the same quarter last year.
The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.
Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
In light of this perspective, let's dive into the average estimates of certain Molina metrics that are commonly tracked and forecasted by Wall Street analysts.
The consensus among analysts is that 'Revenue- Premium revenue- Marketplace' will reach $643.41 million. The estimate indicates a change of -46.4% from the prior-year quarter.
Based on the collective assessment of analysts, 'Revenue- Premium tax revenue' should arrive at $437.04 million. The estimate suggests a change of +1.4% year over year.
Analysts predict that the 'Revenue- Premium revenue- Medicaid' will reach $8.16 billion. The estimate indicates a year-over-year change of +1.6%.
According to the collective judgment of analysts, 'Revenue- Premium revenue- Medicare' should come in at $1.63 billion. The estimate indicates a change of +1.2% from the prior-year quarter.
The average prediction of analysts places 'MCR - Medicaid' at 92.9%. Compared to the present estimate, the company reported 91.3% in the same quarter last year.
The collective assessment of analysts points to an estimated 'MCR - Medicare' of 93.7%. Compared to the present estimate, the company reported 90.0% in the same quarter last year.
Analysts expect 'MCR - Marketplace' to come in at 84.9%. Compared to the current estimate, the company reported 85.4% in the same quarter of the previous year.
The consensus estimate for 'Ending Membership by Program - Total' stands at 5.00 million. The estimate is in contrast to the year-ago figure of 5.75 million.
It is projected by analysts that the 'Ending Membership by Program - Medicaid' will reach 4.48 million. Compared to the current estimate, the company reported 4.77 million in the same quarter of the previous year.
Analysts' assessment points toward 'Ending Membership by Program - Medicare' reaching 230.66 thousand. The estimate compares to the year-ago value of 267.00 thousand.
Analysts forecast 'Ending Membership by Program - Marketplaces' to reach 285.05 thousand. The estimate is in contrast to the year-ago figure of 690.00 thousand.
The combined assessment of analysts suggests that 'MCR - Total' will likely reach 92.5%. Compared to the present estimate, the company reported 90.4% in the same quarter last year.
View all Key Company Metrics for Molina here>>>
Molina shares have witnessed a change of +16.4% in the past month, in contrast to the Zacks S&P 500 composite's -0.6% move. With a Zacks Rank #3 (Hold), MOH is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
, /PRNewswire/ -- S&P SmallCap 600 constituent Molina Healthcare Inc. (NYSE: MOH) will replace National Storage Affiliates Trust (NYSE: NSA) in the S&P MidCap 400, and Construction Partners Inc. (NASD: ROAD) will replace Molina Healthcare in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 22. S&P 500 constituent Public Storage (NYSE: PSA) is acquiring National Storage Affiliates Trust in a deal that is expected to be completed on or about that date pending final conditions.
Following is a summary of the changes that will take place prior to the open of trading on the effective date:
Effective Date
Index Name
Action
Company Name
Ticker
GICS Sector
July 22, 2026
S&P MidCap 400
Addition
Molina Healthcare
MOH
Health Care
July 22, 2026
S&P MidCap 400
Deletion
National Storage Affiliates Trust
NSA
Real Estate
July 22, 2026
S&P SmallCap 600
Addition
Construction Partners
ROAD
Industrials
July 22, 2026
S&P SmallCap 600
Deletion
Molina Healthcare
MOH
Health Care
ABOUT S&P DOW JONES INDICES
S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.
S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spglobal.com/spdji/en/.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels.
On top of the Zacks Rank, investors can also look at our innovative Style Scores system to find stocks with specific traits. For example, value investors will want to focus on the "Value" category. Stocks with high Zacks Ranks and "A" grades for Value will be some of the highest-quality value stocks on the market today.
Molina Healthcare (MOH - Free Report) is a stock many investors are watching right now. MOH is currently sporting a Zacks Rank #2 (Buy) and an A for Value. The stock is trading with a P/E ratio of 9.08, which compares to its industry's average of 18.19. Over the last 12 months, MOH's Forward P/E has been as high as 13.98 and as low as 6.48, with a median of 11.46.
Another notable valuation metric for MOH is its P/B ratio of 2.06. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. MOH's current P/B looks attractive when compared to its industry's average P/B of 2.73. Over the past 12 months, MOH's P/B has been as high as 4.44 and as low as 1.79, with a median of 3.71.
Value investors also frequently use the P/S ratio. This metric is found by dividing a stock's price with the company's revenue. This is a popular metric because sales are harder to manipulate on an income statement, so they are often considered a better performance indicator. MOH has a P/S ratio of 0.26. This compares to its industry's average P/S of 0.35.
Value investors will likely look at more than just these metrics, but the above data helps show that Molina Healthcare is likely undervalued currently. And when considering the strength of its earnings outlook, MOH sticks out as one of the market's strongest value stocks.
Molina (MOH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Before Michael Burry shut down Scion Asset Management in late 2025 and pivoted to publishing a Substack newsletter warning of an “AI Bubble,” his final 13F filings reportedly disclosed put options against NVIDIA (NASDAQ:NVDA | NVDA Price Prediction) and Palantir (NASDAQ:PLTR) alongside a heavy rotation, around 51% of the disclosed portfolio, into health insurer Molina Healthcare. That is the documented record, a snapshot rather than a live position.
This distinction matters because Burry of The Big Short fame is now an opinion writer, not a regulated filer. Scion was deregistered, so there are no ongoing 13F disclosures to verify what he holds right now. His current commentary lives on his newsletter. The trades below are a snapshot of how he was positioned before closing the fund, paired with his ongoing public warnings about AI-era valuations.
What the final filings actually said The pairing was tidy. Short the most crowded story in the market, long the most ignored one. The puts targeted NVIDIA and Palantir, the two names most often used as shorthand for AI-infrastructure excess. NVIDIA carries a market capitalization of roughly $4.95 trillion and a price-to-sales ratio of 19.5. NVIDIA’s forward P/E of 23x looks restrained next to Palantir, which trades at elevated multiples on both earnings and book value.
The long side was Molina Healthcare (NYSE:MOH), a Medicaid-focused managed-care operator whose shares are down 34% over the past year and trade at a price-to-sales ratio of 0.2x. The contrast is the entire trade.
The thesis, reconstructed from the data On NVIDIA, the bear case sidesteps the operating business entirely. Q1 FY27 revenue grew 85.2% year over year to $81.61 billion, with Data Center revenue up 92%. The bear case is that hyperscaler capex cycles historically revert, that the Q2 guide assumes zero Data Center compute revenue from China, and that $119 billion of supply commitments sit on the balance sheet against customer concentration that has rarely looked this top-heavy. The stock is down 8% over the past month even as fundamentals beat estimates.
Molina is the mirror image. Q4 2025 produced an adjusted loss of $2.75 per share against a $0.50 estimate, dragged down by roughly $2.00 per share of unfavorable California Medicaid retroactive premium adjustments plus surging Medicare and Marketplace costs. CEO Joseph Zubretsky called 2026 “a trough year for Medicaid industry margins” and pointed to more than $11.00 per share of embedded earnings from new contracts in California, Texas, Georgia, Ohio and others between 2027 and 2029. The company executed a $1 billion buyback in FY25 at depressed prices. That is the contrarian setup: identifiable margin trough, contracted growth, shrinking share count.
What a retirement investor should actually take from this Copying the short side is the wrong lesson. Put options expire, Scion no longer files, and Burry has been early or wrong on macro calls between the housing trade and now. The 13F snapshot captures only what he believed at one moment in the past.
The long side is more useful. Molina trades at a forward P/E of 21x (on 2027 earnings), with an analyst sentiment that skews cautious: 13 holds against 4 buys. Shares have rallied 9.6% year to date, suggesting the trough-margin narrative is starting to find buyers. For a retirement-focused portfolio, the thesis worth studying is the patient one: own the cyclical bottom of an essential service business, collect the buyback yield, and wait for rate restoration. That is a thesis you can underwrite yourself. The NVIDIA puts are theater.
Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.
Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by the market at large.
In addition to the Zacks Rank, investors looking for stocks with specific traits can utilize our Style Scores system. Of course, value investors will be most interested in the system's "Value" category. Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment.
One stock to keep an eye on is Molina Healthcare (MOH - Free Report) . MOH is currently holding a Zacks Rank #2 (Buy) and a Value grade of A. The stock has a Forward P/E ratio of 9.08. This compares to its industry's average Forward P/E of 18.06. MOH's Forward P/E has been as high as 13.98 and as low as 6.48, with a median of 11.46, all within the past year.
Investors should also recognize that MOH has a P/B ratio of 2.06. Investors use the P/B ratio to look at a stock's market value versus its book value, which is defined as total assets minus total liabilities. This company's current P/B looks solid when compared to its industry's average P/B of 2.69. Over the past year, MOH's P/B has been as high as 4.44 and as low as 1.79, with a median of 3.71.
Value investors also love the P/S ratio, which is calculated by simply dividing a stock's price with the company's sales. This is a preferred metric because revenue can't really be manipulated, so sales are often a truer performance indicator. MOH has a P/S ratio of 0.23. This compares to its industry's average P/S of 0.33.
These are just a handful of the figures considered in Molina Healthcare's great Value grade. Still, they help show that the stock is likely being undervalued at the moment. Add this to the strength of its earnings outlook, and we can clearly see that MOH is an impressive value stock right now.
CompaniesMay 8 (Reuters) - Molina Healthcare (MOH.N), opens new tab on Friday forecast its 2029 adjusted profit at about five times its 2026 outlook, provided the health insurer can keep medical costs in check.
However, J.P. Morgan and Barclays analysts said the forecast fell short of investor expectations, sending its shares down 5%.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
The forecast suggests Molina will "present significant earnings power in 2029; however, we think much of the investor focus is on the path to those earnings and any embedded conservatism," J.P. Morgan analysts said.
Health insurers, including Molina, UnitedHealth (UNH.N), opens new tab and Elevance (ELV.N), opens new tab, reported strong first-quarter results, signaling easing healthcare service costs after more than two years of margin pressure from elevated expenses.
Medical costs for major health insurers were below estimates during the first-quarterMolina projects 2029 premium revenue of about $64 billion, up from around $42 billion it expects in 2026. It sees 2029 adjusted profit between $20 and $30 per share, compared with at least $5 per share in 2026.
A key highlight was Molina's new pre-tax margin goal of around 2% to 3% for 2029 as opposed to about 4% to 5% previously, said Mizuho's Ann Hynes. "While lower ... this goal is achievable for the company."
The profit forecast is a "very solid baseline" if medical cost trends moderate and government reimbursement rates catch up faster, CEO Joe Zubretsky said at the company's investor day, adding that high medical costs will stabilize.
"Maybe it already has, but we have to wait and see in 2026 whether the second- and third-quarter data points support that."
The company said enrollment in government-backed Medicaid plans is expected to decline 2% to 3% annually through 2029, pressured by provisions in U.S. President Donald Trump's One Big Beautiful Bill Act.
Molina primarily sells Medicaid plans to low-income Americans, jointly funded by state and federal governments. It also offers coverage under the Affordable Care Act, commonly known as Obamacare.
Reporting by Mariam Sunny, Sneha S K and Puyaan Singh in Bengaluru; Editing by Shreya Biswas and Vijay Kishore
Our Standards: The Thomson Reuters Trust Principles., opens new tab
LANSING, Mich.--(BUSINESS WIRE)--Molina Healthcare of Michigan (“Molina”), in collaboration with The MolinaCares Accord (“MolinaCares”), announced a series of grants for libraries across the state to develop programming addressing loneliness and social isolation. The $130,000 donation to the Superiorland Library Cooperative will be distributed to 22 libraries to be used for initiatives like caregiver support, digital literacy, and wellness programming.
Social isolation is a major concern for aging adults. The higher risk of mortality associated with social isolation and loneliness is similar in scale to known health risks of cardiovascular disease, smoking, hypertension, and diabetes. Data show lacking social connection increased the risk of premature death by more than 60%.
“Libraries serve as all-inclusive community anchors, providing innovative programs and safe spaces for all,” said Tricia Wylie, director of the Superiorland Library Cooperative. “The Molina Healthcare of Michigan grants support libraries as lifelines of connection, helping reduce loneliness and isolation by bringing people together and strengthening community well-being.”
“Molina believes in a comprehensive approach to wellness by providing high-quality care and support programs that address critical determinants of health,” said Terrisca Des Jardins, plan president for Molina Healthcare of Michigan. “This grant allows evidence-based initiatives to be taken to scale by expanding the skillsets of those giving care to seniors in each community.”
The recipients of the grants are Bay County Library System, Brandon Township Public Library, Brown City District Library, Commerce Township Community Library, Farmington Community Library, Flint District Library, Fowlerville District Library, Fruitport District Library, Leighton Township Library, Lincoln Township Public Library, Marcellus Township Wood Memorial Library, Oak Park Public Library, Ogemaw District Library, Otsego District Library, Oxford Public Library, Spring Lake District Library, St. Charles District Library, Thomas E. Fleschner Memorial Library, Trenton Veterans Memorial Library, West Bloomfield Township Public Library, William P. Faust Westland Public Library, and Ypsilanti District Library.
About Molina Healthcare of Michigan
Molina Healthcare of Michigan, Inc. provides government-funded, quality health care, serving members through Medicaid, Medicare, and Marketplace programs in Michigan. Through its locally operated health plans, Molina Healthcare, Inc., a Fortune 500 company, provides managed health care services under the Medicaid and Medicare programs, and through state insurance marketplaces. For more information about Molina Healthcare of Michigan, visit MolinaHealthcare.com.
About The MolinaCares Accord
Established by Molina Healthcare, Inc., The MolinaCares Accord oversees a community investment platform created to improve the health and well-being of disadvantaged populations by funding meaningful, measurable, and innovative programs and solutions that improve health, life, and living in local communities.
LAWRENCE, Mass.--(BUSINESS WIRE)--Molina Healthcare and The MolinaCares Accord donate $120,000 to support programming for young adults with disabilities.
The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong picks.
Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use tried-and-true metrics and fundamental analysis to find companies that they believe are undervalued at their current share price levels.
In addition to the Zacks Rank, investors looking for stocks with specific traits can utilize our Style Scores system. Of course, value investors will be most interested in the system's "Value" category. Stocks with "A" grades for Value and high Zacks Ranks are among the best value stocks available at any given moment.
Molina Healthcare (MOH - Free Report) is a stock many investors are watching right now. MOH is currently sporting a Zacks Rank #2 (Buy), as well as an A grade for Value. The stock is trading with P/E ratio of 9.08 right now. For comparison, its industry sports an average P/E of 16.80. Over the past year, MOH's Forward P/E has been as high as 13.98 and as low as 6.48, with a median of 11.46.
Another valuation metric that we should highlight is MOH's P/B ratio of 2.06. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. MOH's current P/B looks attractive when compared to its industry's average P/B of 2.46. Over the past year, MOH's P/B has been as high as 4.44 and as low as 1.79, with a median of 3.71.
Value investors also use the P/S ratio. The P/S ratio is calculated as price divided by sales. Some people prefer this metric because sales are harder to manipulate on an income statement. This means it could be a truer performance indicator. MOH has a P/S ratio of 0.21. This compares to its industry's average P/S of 0.28.
Finally, our model also underscores that MOH has a P/CF ratio of 7.07. This metric takes into account a company's operating cash flow and can be used to find stocks that are undervalued based on their solid cash outlook. This stock's P/CF looks attractive against its industry's average P/CF of 19.57. Within the past 12 months, MOH's P/CF has been as high as 16.68 and as low as 6.15, with a median of 12.60.
These are just a handful of the figures considered in Molina Healthcare's great Value grade. Still, they help show that the stock is likely being undervalued at the moment. Add this to the strength of its earnings outlook, and we can clearly see that MOH is an impressive value stock right now.
Pfizer (NYSE:PFE | PFE Price Prediction) at $25.75, Molina Healthcare (NYSE:MOH) at $186.80, and Halliburton (NYSE:HAL) at $41.29 trade at defensive, cash-generative valuations. Michael Burry purchased these shares for their real earnings and margin stability, and with inflation still pressuring margins across the market, names that generate cash, hold pricing power, and trade at sober multiples carry a structural edge.
Each of these companies sits in a defensive corner of its sector. Pfizer is a low-beta pharma giant lapping the COVID cliff. Molina is a Medicaid-focused managed care operator working through a self-described trough year. Halliburton is an oilfield services leader leveraged to a sharp recovery in crude prices.
Pfizer: A 6.66% Yield and a Forward Multiple That Smells Like a Rebound Pfizer trades at a forward P/E of 9 against a trailing P/E of 20, with the gap reflecting analyst expectations for earnings expansion as the COVID drag fades. The 6.66% dividend yield is rare among large-cap pharma, and the 0.305 beta puts Pfizer among the least volatile names in the S&P 500.
The non-COVID portfolio grew 9% operationally in Q4 2025, and management has flagged roughly 20 pivotal trial starts ahead, including obesity assets from the Metsera acquisition. The analyst target of $29.11 implies meaningful upside from here, and shares are up 25.15% over the past year. Targets are not guarantees, but 11 of 29 covering analysts rate the stock Buy or Strong Buy, with only 3 at Sell or Strong Sell.
Molina Healthcare: Buying the Trough Molina cratered after Q4 2025, when adjusted EPS came in at a $2.75 loss against a $0.50 consensus. CEO Joseph Zubretsky has since framed 2026 as “a trough year for Medicaid industry margins“, with embedded earnings exceeding $11.00 per share targeted for 2027 through 2029 as new contracts mature.
The stock has already rallied 26.64% in the past month as buyers look past the trough. The analyst target sits at $182.25, roughly even with the current price, meaning upside comes from earnings recovery rather than multiple expansion. With a 0.848 beta and exposure to non-discretionary government healthcare spending, Molina is a contrarian inflation hedge.
Halliburton: Cash Flow Riding a Crude Recovery Halliburton’s Q1 2026 print delivered EPS of $0.55 against a $0.50 estimate on revenue of $5.40 billion. WTI crude has climbed from $57.97 in December 2025 to $100.32 in April 2026, a powerful tailwind for oilfield services demand.
Management returned 85% of free cash flow to shareholders in 2025 through $1 billion in buybacks and a steady $0.17 quarterly dividend. CEO Jeff Miller describes North America as in the “early innings of a recovery”. Shares are up 46.83% year to date, and the $42.36 analyst target alongside 19 Buy or Strong Buy ratings versus 3 Sells points to continued institutional conviction.
Why Burry’s Playbook Fits This Tape At $25.75, $186.80, and $41.29, Pfizer, Molina, and Halliburton share a defensive valuation profile. Each name earns its keep through cash flow first. Pfizer’s pipeline plus a near-7% yield pays investors to wait through the patent cliff. Molina’s trough year resets the bar low enough that any rate normalization snaps earnings back hard. Halliburton’s capital return discipline turns a cyclical business into a shareholder yield machine while crude trends higher.
The shared risk is a recession that drags all three down together. The shared edge is a valuation that already discounts the bad news. For investors hedging inflation with durable cash earnings, the Burry basket holds up at these prices.
Shares of Molina (MOH - Free Report) have been struggling lately and have lost 5.5% over the past two weeks. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road.
While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the future earnings of this provider of Medicaid-related services is a solid fundamental factor that enhances the prospects of a trend reversal for the stock.
What is a Hammer Chart and How to Trade It?This is one of the popular price patterns in candlestick charting. A minor difference between the opening and closing prices forms a small candle body, and a higher difference between the low of the day and the open or close forms a long lower wick (or vertical line). The length of the lower wick being at least twice the length of the real body, the candle resembles a 'hammer.'
In simple terms, during a downtrend, with bears having absolute control, a stock usually opens lower compared to the previous day's close, and again closes lower. On the day the hammer pattern is formed, maintaining the downtrend, the stock makes a new low. However, after eventually finding support at the low of the day, some amount of buying interest emerges, pushing the stock up to close the session near or slightly above its opening price.
When it occurs at the bottom of a downtrend, this pattern signals that the bears might have lost control over the price. And, the success of bulls in stopping the price from falling further indicates a potential trend reversal.
Hammer candles can occur on any timeframe -- such as one-minute, daily, weekly -- and are utilized by both short-term as well as long-term investors.
Like every technical indicator, the hammer chart pattern has its limitations. Particularly, as the strength of a hammer depends on its placement on the chart, it should always be used in conjunction with other bullish indicators.
Here's What Increases the Odds of a Turnaround for MOHThere has been an upward trend in earnings estimate revisions for MOH lately, which can certainly be considered a bullish indicator on the fundamental side. That's because a positive trend in earnings estimate revisions usually translates into price appreciation in the near term.
The consensus EPS estimate for the current year has increased 3.8% over the last 30 days. This means that the Wall Street analysts covering MOH are majorly in agreement about the company's potential to report better earnings than what they predicted earlier.
If this is not enough, you should note that MOH currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. And stocks carrying a Zacks Rank #1 or 2 usually outperform the market. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Moreover, a Zacks Rank of 2 for Molina is a more conclusive indication of a potential trend reversal, as the Zacks Rank has proven to be an excellent timing indicator that helps investors identify precisely when a company's prospects are beginning to improve.
It has been about a month since the last earnings report for Molina (MOH - Free Report) . Shares have added about 3.8% in that time frame, underperforming the S&P 500.
But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Molina due for a pullback? Well, first let's take a quick look at the most recent earnings report in order to get a better handle on the recent drivers for Molina Healthcare, Inc before we dive into how investors and analysts have reacted as of late.
MOH Q1 EPS Tops Estimates on Lower Medical Costs, Membership Declines
Molina Healthcare reported first-quarter 2026 adjusted earnings per share (EPS) of $2.35, which beat the Zacks Consensus Estimate of $1.57. The bottom line declined 61.3% from the year-ago period's level.
Revenues amounted to $10.8 billion, which decreased 3.1% year over year. The top line marginally missed the consensus mark by 0.2%.
The first-quarter performance was supported by lower medical care costs, partially offset by declining premiums, membership and investment income.
MOH’s Q1 Operational UpdatePremium revenues of $10.2 billion decreased 4.3% year over year in the quarter under review and missed the Zacks Consensus Estimate by 0.2%. The decline was due to reduced memberships, reflecting product and pricing decisions.
As of March 31, 2026, total membership decreased 12.5% year over year to around 5 million and missed the Zacks Consensus Estimate by 1.2%. The health insurer witnessed a year-over-year decrease in customers across all segments, especially in Marketplace and Other.
Investment income fell 9.3% year over year to $98 million. It missed the Zacks Consensus Estimate of $100.8 million.
Total operating expenses were $10.71 billion, flat year over year and slightly below our model estimate of $10.72 billion, driven by lower medical care costs. The adjusted general and administrative expense ratio increased to 6.9% in the first quarter from 6.3% a year ago. Interest expenses of $54 million rose from $43 million in the prior year.
The consolidated medical care ratio (medical costs as a percentage of premium revenues), or MCR, was 91.1% in the reported quarter. It rose from 89.2% a year ago but was below the Zacks Consensus Estimate of 91.5%.
Molina Healthcare’s adjusted net income decreased 64% year over year to $120 million.
MOH’s Financial Update (as of March 31, 2026)Molina Healthcare exited the first quarter with cash and cash equivalents of $5.3 billion, which increased from the 2025-end level of $4.2 billion. Total assets of $16.4 billion rose from $15.6 billion at 2025-end.
Long-term debt was $3.8 billion, unchanged from the 2025-end levels.
Total stockholders’ equity of $4.08 billion rose from $4.07 billion at the end of 2025.
Net cash provided by operating activities amounted to $1.1 billion in the first quarter of 2026 compared with $190 million in the prior year.
MOH’s 2026 GuidanceThe company's full-year 2026 premium revenue guidance has remained unchanged at about $42 billion, down roughly 2% from 2025.
Management expects 2026 GAAP earnings of at least $1.90 per diluted share. It has reaffirmed adjusted earnings guidance of at least $5.00 per diluted share.
Adjusted net income is projected to be $256 million, while GAAP net income is expected to reach $97 million in 2026.
How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in estimates revision.
The consensus estimate has shifted -13.64% due to these changes.
VGM ScoresCurrently, Molina has a average Growth Score of C, though it is lagging a lot on the Momentum Score front with an F. However, the stock has a grade of A on the value side, putting it in the top quintile for value investors.
Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.
OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Molina has a Zacks Rank #2 (Buy). We expect an above average return from the stock in the next few months.
Performance of an Industry PlayerMolina belongs to the Zacks Medical - HMOs industry. Another stock from the same industry, UnitedHealth Group (UNH - Free Report) , has gained 7.9% over the past month. More than a month has passed since the company reported results for the quarter ended March 2026.
UnitedHealth reported revenues of $111.72 billion in the last reported quarter, representing a year-over-year change of +2%. EPS of $7.23 for the same period compares with $7.20 a year ago.
For the current quarter, UnitedHealth is expected to post earnings of $4.84 per share, indicating a change of +18.6% from the year-ago quarter. The Zacks Consensus Estimate has changed +1.5% over the last 30 days.
UnitedHealth has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of B.
On May 26, 2026, Molina Healthcare Inc MOH shares fell 4.3% today, closing at $176.20. The stock has experienced a volatile trading range over the past year, peaking at $311.53 and dipping to a low of $121.06. This performance highlights the challenges faced by the company in recent times.
GF Value™ verdict: Currently priced at $176.20, which is 56.2% below the estimated fair value of $402.13.GF Score™: 75/100, indicating that the stock is above average in its overall quality.Most notable signal: Insiders sold $3.5M in the last 3 months, with no buying activity reported. Is MOH Overvalued or Undervalued? Molina Healthcare Inc MOH is currently trading at $176.20, significantly below its GF Value™ of $402.13. This pricing indicates that the stock is 56.2% undervalued, presenting a compelling opportunity for potential investors. The GF Valuation label categorizes the stock as significantly undervalued, suggesting that there is a substantial margin of safety for investors considering the stock at its current price. GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.
However, while the undervaluation presents an opportunity, it is crucial to consider the broader market environment and the company's financial health, as reflected in its recent stock performance and insider activity. The absence of insider buying coupled with substantial selling can indicate a lack of confidence by those closest to the company, which is a risk factor that potential investors should weigh carefully.
How Does MOH's Valuation Compare to Its History? MetricCurrentHistorical P/E (TTM)52.1x20.4x Forward P/E33.9xN/A The current P/E ratio of 52.1x is significantly above its 5-year median P/E of 20.4x, indicating that the stock is trading at a premium compared to its historical valuation metrics. The forward P/E of 33.9x also suggests higher anticipated earnings. This P/E analysis is in contrast to the GF Value™ verdict, which classifies the stock as significantly undervalued. The high current P/E may reflect market sentiment and expectations that do not align with the intrinsic value suggested by the GF Value™ analysis.
What Does MOH's GF Score™ Tell Us? MetricRating GF Score™75 Financial Strength7/10 Profitability8/10 Growth7/10 Valuation2/10 Momentum4/10 The GF Score™ of 75/100 indicates that Molina Healthcare is above average in quality, particularly in terms of profitability, where it scores 8/10. Financial strength is also solid at 7/10, and growth ranks similarly. However, the valuation score of 2/10 is a significant concern, highlighting that current market prices may not reflect the stock's true value. The momentum rank of 4/10 suggests that the stock is not performing strongly in terms of price trends, which further adds to the caution investors should exercise.
What Are Insiders Doing with MOH Stock? In the last three months, insiders have sold $3.5 million worth of Molina Healthcare stock, with no buying activity reported. This trend of insider selling can often be interpreted as a lack of confidence in the company's future prospects or a response to current market conditions. When insiders sell such a significant amount without any buying, it raises questions about the company's near-term outlook. Investors may want to consider this insider activity as part of their decision-making process.
What This Means for Investors Based on the analysis of GF Value™, Molina Healthcare Inc MOH is currently undervalued at $176.20, presenting a potential opportunity for long-term investors. However, the high P/E ratio and recent insider selling suggest caution is warranted. Investors should weigh these signals carefully before making any decisions.
For the complete analysis, visit the Molina Healthcare Inc MOH stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is MOH's GF Score™?
MOH has a GF Score™ of 75/100, indicating that it is above average in quality and has the potential to generate favorable long-term returns.
Is MOH overvalued or undervalued?
MOH is currently undervalued according to GF Value™, which estimates its fair value at $402.13, making the current price of $176.20 56.2% below this estimate.
What is MOH's P/E ratio?
MOH's P/E ratio is currently 52.1x, which is significantly above its historical 5-year median P/E of 20.4x, indicating that the stock is trading at a premium compared to its historical valuation.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Key Takeaways Molina Healthcare trades at 26.83X P/E, above the industry average of 17.09X and its 5-year median.MOH reaffirmed 2026 premium revenue guidance near $42B despite lower Medicaid membership.Molina Healthcare ended Q1 2026 with $5.3B cash and operating cash flow rising to $1.1B. Molina Healthcare, Inc. (MOH - Free Report) is a multi-state managed care organization that provides healthcare services under Medicaid, Medicare and state insurance marketplaces. The company operates through four segments — Medicaid, Medicare, Marketplace and Other — with a primary focus on delivering affordable healthcare coverage to low-income individuals and families.
Headquartered in Long Beach, CA, it carries a market capitalization of nearly $9.2 billion. The stock has gained 18.8% over the past six months, outperforming the industry’s 17.3% growth. MOH currently trades at a trailing 12-month P/E ratio of 26.83X, higher than the industry average of 17.09X, reflecting investors’ confidence in its long-term growth prospects and operational strength.
Supported by solid fundamentals, the stock currently carries a Zacks Rank #2 (Buy).
Where Do Estimates for MOH Stand?The Zacks Consensus Estimate for Molina Healthcare’s 2026 earnings is pegged at $5.23 per share. In the past 60 days, it has witnessed five upward estimate revisions against none in the opposite direction. The consensus estimate for revenues is pegged at $44.07 billion for 2026. The 2027 revenue estimate is pegged at $46.4 billion, indicating a 5.3% year-over-year increase.
Molina Healthcare, Inc Price, Consensus and EPS Surprise
MOH’s Growth DriversMOH has steadily expanded its market presence through strategic acquisitions across Medicaid, Medicare and long-term care programs, strengthening its geographic footprint and broadening its service capabilities. The company also maintains solid financial flexibility for future expansion, with no borrowings under its $1.25 billion revolving credit facility and access to up to $800 million in incremental term-loan capacity. Further, its return on invested capital (ROIC) of 7% compares with the industry average of 5.5%, highlighting disciplined capital deployment and efficient integration of acquired businesses.
Molina Healthcare’s premium revenues declined 4.3% year over year to $10.2 billion in the first quarter of 2026 due to lower Medicaid and Marketplace membership. However, the company reaffirmed its full-year 2026 premium revenue guidance of nearly $42 billion, reflecting management’s confidence in the stability of its core business.
Expense discipline remains a key strength for Molina Healthcare, with the adjusted G&A ratio improving 50 basis points in 2024 and another 20 basis points in 2025. Although the adjusted G&A ratio increased to 6.9% in first-quarter 2026 from 6.3% a year ago, management still expects the full-year ratio to remain around 6.4% reflecting ongoing scalability initiatives.
Molina Healthcare exited first-quarter 2026 with a strong balance sheet. As of March 31, 2026, it held $5.3 billion in cash and cash equivalents against long-term debt of $3.8 billion. Operating cash flow surged to $1.1 billion from $190 million in the prior-year quarter, reflecting solid cash generation. Its healthy liquidity profile provides flexibility to support contractual capital needs, invest in growth opportunities and navigate industry volatility.
Risks to ConsiderThere are a few factors investors should monitor closely.
Molina Healthcare continues to face pressure from elevated medical costs, with its consolidated MCR rising to 91.1% in first-quarter 2026 from 89.2% a year ago. Management also expects Medicaid and Marketplace MCRs to remain elevated through 2026, which could weigh on margin recovery.
MOH trades at a premium valuation, with a forward P/E of 26.83X compared with the industry average of 17.09X and its five-year median of 14.69X. The stretched valuation may limit upside potential if earnings growth remains under pressure.
Other Key PicksSome other top-ranked stocks in the Medical space are Centene Corporation (CNC - Free Report) , The Joint Corp. (JYNT - Free Report) and Indivior Pharmaceuticals, Inc. (INDV - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Centene’s 2026 earnings is pegged at $3.47 per share, indicating 66.8% year-over-year growth. It has witnessed nine upward revisions in the past 30 days, with no movement in the opposite direction. CNC beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 74.9%. The consensus estimate for 2026 revenues is pinned at $191.03 billion.
The Zacks Consensus Estimate for Joint’s 2026 earnings is pegged at 51 cents per share, which has witnessed two upward revisions in the past 30 days, with no movement in the opposite direction. JYNT beat earnings estimate in each of the trailing four quarters, with the average surprise being 125.24%. The consensus estimate for 2026 revenues is pinned at $61.11 million, indicating an 11.3% year-over-year increase.
The Zacks Consensus Estimate for Indivior Pharmaceuticals’ 2026 earnings is pegged at $3.35 per share, indicating a 34% year-over-year improvement. INDV beat earnings estimates in each of the trailing four quarters, with the average surprise being 65.44%. The consensus estimate for 2026 revenues is pinned at $1.26 billion, implying 1.5% year-over-year growth.
ALBUQUERQUE, N.M.--(BUSINESS WIRE)--As rising living costs continue to impact families across Bernalillo County—from housing and utility expenses to access-to-care challenges—Molina Healthcare of New Mexico (“Molina”) will officially open a new One Stop Help Center in Albuquerque with a ribbon-cutting ceremony on Friday, May 29.
The Albuquerque location is the third Molina One Stop Help Center in New Mexico, and the second to open this month, marking continued investment in communities with the highest need. The site expands a growing network designed to close gaps in care by connecting residents directly to critical health and social services at no cost, all in one centralized location.
Remarks will be provided by Dr. Darcie Robran Marquez, plan president of Molina Healthcare of New Mexico, alongside Molina leadership and community partners. A local priest will also deliver a blessing.
The Molina One Stop Help Center is open to the entire community and offers in-person support for:
Healthcare enrollment assistance and provider navigation Utility assistance for internet, electricity, water, and gas services Short-term shelter support and connections to long-term housing resources Food access, including referrals to local food banks and pantries Additional services, including TeleHealth, disease management education, child and adult wellness support, reading circles, and more “Molina Healthcare of New Mexico is proud to deepen our commitment to Albuquerque and Bernalillo County,” said Dr. Darcie Robran Marquez, plan president of Molina Healthcare of New Mexico. “This One Stop Help Center is designed with the community in mind—bringing vital health and social services under one roof, strengthening local partnerships, and making it easier for individuals and families to get the support they need, close to home.”
The Molina One Stop Help Center is open Monday through Thursday, 9:00 a.m. to 5:00 p.m. and Friday, 9:00 a.m. to 4:30 p.m.
Ribbon Cutting Ceremony:
WHEN:
Friday, May 29, 2026 at 11:00 a.m.
WHERE:
Molina Healthcare of New Mexico One Stop Help Center
4411 San Mateo Blvd NE, Suite E16
Albuquerque, NM 87109
WHO:
(On-site media contact): Roy Rivas
Molina Healthcare of New Mexico [email protected]
505-706-6334
MEDIA WELCOME TO ATTEND
About Molina Healthcare of New Mexico:
Molina Healthcare of New Mexico, Inc. provides government‑funded, quality health care to residents through Medicaid and Marketplace programs statewide. Operating locally as part of Molina Healthcare, Inc., a Fortune 500 company, Molina delivers managed health care services under Medicaid, Medicare, and state insurance marketplaces.
Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.
Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving room for profits.
On top of the Zacks Rank, investors can also look at our innovative Style Scores system to find stocks with specific traits. For example, value investors will want to focus on the "Value" category. Stocks with high Zacks Ranks and "A" grades for Value will be some of the highest-quality value stocks on the market today.
One company value investors might notice is Molina Healthcare (MOH - Free Report) . MOH is currently sporting a Zacks Rank #2 (Buy), as well as a Value grade of A. The stock is trading with P/E ratio of 9.08 right now. For comparison, its industry sports an average P/E of 16.61. Over the last 12 months, MOH's Forward P/E has been as high as 13.98 and as low as 6.48, with a median of 11.46.
Another notable valuation metric for MOH is its P/B ratio of 2.06. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. This company's current P/B looks solid when compared to its industry's average P/B of 2.45. MOH's P/B has been as high as 4.44 and as low as 1.79, with a median of 3.71, over the past year.
Value investors also frequently use the P/S ratio. This metric is found by dividing a stock's price with the company's revenue. Some people prefer this metric because sales are harder to manipulate on an income statement. This means it could be a truer performance indicator. MOH has a P/S ratio of 0.21. This compares to its industry's average P/S of 0.27.
Finally, investors will want to recognize that MOH has a P/CF ratio of 7.07. This metric takes into account a company's operating cash flow and can be used to find stocks that are undervalued based on their solid cash outlook. MOH's current P/CF looks attractive when compared to its industry's average P/CF of 19.51. Within the past 12 months, MOH's P/CF has been as high as 16.68 and as low as 6.15, with a median of 12.60.
Value investors will likely look at more than just these metrics, but the above data helps show that Molina Healthcare is likely undervalued currently. And when considering the strength of its earnings outlook, MOH sticks out as one of the market's strongest value stocks.
On June 01, 2026, Molina Healthcare Inc MOH shares rose 5.6% to a current price of $183.25. This move comes amidst a challenging year, where the stock has seen a 52-week range between $121.06 and $311.53.
GF Value™ verdict indicates that the current price is significantly undervalued at $183.25 compared to the GF Value™ estimate of $402.03, representing a 54.4% upside.GF Score™ stands at 78/100, suggesting that the stock is above average in terms of its fundamental performance.Most notable signal is the insider activity, with insiders having sold $3.5 million worth of shares in the last three months without any buying activity. Is MOH Overvalued or Undervalued? Based on the current price of $183.25 and the GF Value™ estimate of $402.03, Molina Healthcare Inc MOH appears significantly undervalued. The 54.4% margin of safety indicates a potential opportunity for long-term investors. The GF Valuation label classifies MOH as significantly undervalued, suggesting that the market may not be fully recognizing the company's intrinsic value.
However, it is essential to consider the risks associated with this valuation. The stock has been underperforming over the past year, down 39.9%, which may reflect underlying challenges that could affect future performance. The GF Value™ is GuruFocus' proprietary measure of intrinsic value, calculated from historical trading multiples, past business growth, and future performance estimates.
How Does MOH's Valuation Compare to Its History? Metric Current Historical P/E (TTM) 54.2x 20.4x Forward P/E 35.2x N/A The current P/E (TTM) of 54.2x is significantly above its 5-year median P/E of 20.4x, suggesting that the stock is trading at a premium compared to its historical valuation. This analysis aligns with the GF Value™ verdict, emphasizing that while the stock may be undervalued in terms of intrinsic value, it is trading at a high valuation relative to its historical earnings.
What Does MOH's GF Score™ Tell Us? Metric Rating GF Score™ 78 Financial Strength 7/10 Profitability 8/10 Growth 7/10 Valuation 2/10 Momentum 7/10 The GF Score™ of 78/100 indicates a solid performance in several key areas, with profitability being the strongest aspect, rated at 8/10. Financial strength and growth also present positively with scores of 7/10. However, the valuation rank of 2/10 highlights that the stock is facing challenges in terms of its valuation metrics, which may be a concern for prospective investors.
What Are Insiders Doing with MOH Stock? In the past three months, insiders have sold $3.5 million worth of Molina Healthcare shares, indicating a lack of confidence in the stock's near-term prospects as there have been no purchases during this period. This selling could be interpreted as a cautionary sign for potential investors, suggesting that insiders may not anticipate significant short-term appreciation in the stock's value.
What This Means for Investors Based on the GF Value™ assessment, Molina Healthcare Inc MOH is currently undervalued. However, the high P/E ratio and recent insider selling may present risks that investors should consider before making any decisions.
For the complete analysis, visit the Molina Healthcare Inc MOH stock page. You can also explore the GF Value™ page for detailed valuation methodology, or use the GuruFocus Stock Screener to find similar opportunities.
Frequently Asked Questions What is MOH's GF Score™?
MOH's GF Score™ is 78/100, indicating that it is above average in terms of its fundamental performance and potential for long-term returns.
Is MOH overvalued or undervalued?
MOH is currently undervalued according to the GF Value™ estimate, suggesting that there is a significant upside potential relative to the current market price.
What is MOH's P/E ratio?
MOH's P/E (TTM) is 54.2x, which is significantly above its 5-year median of 20.4x, indicating that the stock is trading at a premium compared to its historical valuation.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
LONG BEACH, Calif.--(BUSINESS WIRE)--Molina Healthcare, Inc. (NYSE: MOH) today announced it will issue its earnings release for the second quarter ending June 30, 2026, after the market closes on Wednesday, July 22, 2026, and will host a conference call and webcast to discuss the earnings release on Thursday, July 23, 2026, at 8:00 a.m. Eastern Time. To access this interactive teleconference, dial (877) 883-0383 and enter the confirmation number, 8631129. A telephonic replay of the conference call will be available through Thursday, July 30, 2026, by dialing (855) 669-9658 and entering the confirmation number, 6469068.
A live broadcast of Molina Healthcare’s conference call will be available on the Company’s investor relations website, investors.molinahealthcare.com. A 30-day online replay will be available shortly following the conclusion of the live broadcast.
About Molina Healthcare
Molina Healthcare, Inc., a FORTUNE 500 company, provides managed healthcare services under the Medicaid and Medicare programs and through the state insurance marketplaces. For more information about Molina Healthcare, please visit MolinaHealthcare.com.
Molina Healthcare (MOH +3.68%) had a good week, at least as far as its stock was concerned. Over the past five trading days, according to data compiled by S&P Global Market Intelligence, the shares raced almost 10% higher, thanks in no small part to a rotation into defensive stocks.
Tech aversion Late in the week, tech stocks in particular crashed fairly hard. Many had jumped higher in recent months because of excitement around the expansion of artificial intelligence (AI). However, no rally lasts forever, and such titles began to take hits on Thursday.
Image source: Getty Images.
The following day, following a far better-than-expected jobs report, investors began to worry that such data increases the chances of interest rate hikes by the Federal Reserve. Higher rates (or the fear of them) tend to drive up bond yields, making such assets more attractive to investors while dampening enthusiasm for riskier plays like tech stocks.
As an insurer and managed care organization (MCO), Molina operates a solid business that is to some extent insulated from economic shocks. It also habitually posts top-line growth and net profits. So for some investors, it's a kind of safe haven in times when the economy starts to seem wobbly.
Today's Change
(
3.68
%) $
7.11
Current Price
$
200.31
Some consider it a safe haven I'm not as worried as some about the near future of risky plays like tech stocks. Nevertheless, Molina is a good choice for those who feel otherwise, particularly since it's a veteran operator that is very effective at both its main businesses. I'd say that makes it a buy these days.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
LONG BEACH, Calif.--(BUSINESS WIRE)--Molina Healthcare, Inc. (NYSE: MOH) (“Molina”) announced today that the Illinois Department of Healthcare and Family Services (HFS) intends to award a HealthChoice Illinois Medicaid Managed Care program contract to Molina’s Illinois health plan subsidiary, Molina Healthcare of Illinois.
The go-live date for the new contract is expected to be January 1, 2027. The contract is expected to have a duration of four-and-a-half years, with the option to extend the contract up to an additional five-and-a-half years at the discretion of the state. Molina Healthcare of Illinois will be one of six health plans offering health care coverage to Illinois’s roughly 3.1 million total Medicaid beneficiaries.
About Molina Healthcare
Molina Healthcare, Inc., a FORTUNE 500 company, provides managed healthcare services under the Medicaid and Medicare programs and through the state insurance marketplaces. For more information about Molina Healthcare, please visit MolinaHealthcare.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995. This press release contains forward-looking statements regarding HFS’s selection of Molina Healthcare of Illinois. All forward-looking statements are based on Molina’s current expectations that are subject to numerous risks and uncertainties that could cause actual results to differ materially. Such risks include, without limitation, a successful protest or legal action, a delay in the start date for the contract, or a contract term that is shorter than expected. Given these risks and uncertainties, Molina cannot give assurances that its forward-looking statements will prove to be accurate. Information regarding the other risk factors to which we are subject is provided in greater detail in our periodic reports and filings with the Securities and Exchange Commission (“SEC”), including our most recent Annual Report on Form 10-K. These reports can be accessed under the investor relations tab of our website or on the SEC’s website at sec.gov.
